Toxic Truths & Dosing Dilemmas

Richmond Pharmacology is excited to join Toxic Truths & Dosing Dilemmas: Navigating Early Drug Development – Translational Aspects of CNS Safety Findings in Oberursel, Germany, on 7–8 May 2026.

This workshop brings together leading experts in early-phase drug development to address critical challenges in CNS safety, dosing strategies, and translational research for safer, more effective therapies.

Representing Richmond Pharmacology

• Dr Jörg Taubel, Chief Executive Officer and President at AGAH

What Makes This Workshop Unique

The AGAH workshop will take a closer look at the regulatory insights and real-world lessons that contributed to the 2018 EMA first-in-human guideline revision—and discuss how this evolving framework supports stronger risk identification, characterization, and mitigation in early clinical development.

Here we will explore how modern regulatory guidance helps refine decision-making in first-in-human trials and improves the translation of early safety assessment results into safer, more informed study designs.

We look forward to connecting with attendees to discuss Richmond’s expertise in:

• CNS safety evaluation in early-phase trials

• Translational approaches to predict and mitigate risk

• Optimizing dosing strategies for novel compounds

• Regulatory considerations for CNS safety findings

• Collaboration between academia, industry, and regulators

Connect With Us

If you are attending AGAH Workshop 2026 and would like to explore partnership or development opportunities email us at:

📧 fasteranswers@richmondpharmacology.com

‍